Salvage Chemotherapy for Metastatic Breast Cancer
Author Information
Author(s): Kalbakis K, Kouroussis Ch, Kakolyris S, Mavroudis D, Souglakos J, Agelaki S, Vamvakas L, Christodoulakis M, Stylianou K, Georgoulias V
Primary Institution: Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion
Hypothesis
The study aims to evaluate the activity and tolerance of high-dose leucovorin and infusional 5-fluorouracil in combination with cyclophosphamide as salvage chemotherapy in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Conclusion
The combination of high-dose 5-FU/LV with conventional doses of cyclophosphamide is a well-tolerated and effective salvage regimen for patients with metastatic breast cancer heavily pretreated with both anthracyclines and taxanes.
Supporting Evidence
- Complete response was achieved in 2 patients (4.9%) and partial response in 9 patients (22%).
- The overall response rate was 26.9%.
- Grade 3/4 neutropenia occurred in 9 patients (22%).
- The median overall survival was 13 months.
- The probability for 1-year survival was 51%.
Takeaway
Doctors tested a new chemotherapy treatment for breast cancer that didn't work with other treatments, and it helped some patients feel better.
Methodology
Patients received cyclophosphamide as an intravenous bolus and high-dose leucovorin and 5-fluorouracil as infusions over specified durations.
Limitations
The study involved a small sample size and was limited to patients heavily pretreated with specific prior therapies.
Participant Demographics
Median age of participants was 59 years, with varying performance statuses and prior chemotherapy regimens.
Statistical Information
P-Value
0.047
Confidence Interval
95% CI: 13.27–40.39%
Statistical Significance
p=0.047
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website